Cite
Luo F, Lu FT, Qiu MZ, et al. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis. 2021;12(8):772doi: 10.1038/s41419-021-04042-7.
Luo, F., Lu, F. T., Qiu, M. Z., Zhou, T., Ma, W. J., Luo, M., Zeng, K. M., Luo, Q. Y., Pan, W. T., Zhang, L., Xia, Z. F., Zhang, Z. H., Cao, J. X., Zhao, H. Y., Zhang, L., & Yang, D. J. (2021). Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell death & disease, 12(8), 772. https://doi.org/10.1038/s41419-021-04042-7
Luo, Fan, et al. "Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway." Cell death & disease vol. 12,8 (2021): 772. doi: https://doi.org/10.1038/s41419-021-04042-7
Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY, Zhang L, Yang DJ. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis. 2021 Aug 05;12(8):772. doi: 10.1038/s41419-021-04042-7. PMID: 34354046; PMCID: PMC8342713.
Copy
Download .nbib